Since most cytotoxic agents currently in use induce apoptosis of cancer cells and survivin upregulation seems to play a pivotal role in resistance to chemo- and radiotherapy [24,101], new classes of targeted drugs are emerging based on strategies to inhibit the expression or function of survivin. This evidence concerns the gene BIRC5 and cancer.